Ad
Monday, 13 January 2020
Switzerland's Obseva eyes China re-start for fertility drug that failed trial
ObsEva struck a pact with China's Yuyuan BioScience Technology to develop and commercialize the fertility drug nolasiban, the Swiss drugmaker said on Monday as it seeks to inject new life into a medicine that had flopped a trial.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment